# AstraZeneca Alexion’s Ultomiris recommended in EU for children with PNH

- Link: https://www.directorstalkinterviews.com/astrazeneca-alexions-ultomiris-recommended-in-eu-for-children-with-pnh/4121011745
- Published: 2021-07-26T07:19:44+01:00
- Author: Amilia Stone

**[AstraZeneca plc](https://www.directorstalkinterviews.com/ftse-company/astrazeneca/azn.l)**(
[LON:AZN](https://www.directorstalkinterviews.com/ftse-company/astrazeneca/azn.l))
Alexion’s _Ultomiris_ (ravulizumab) has been recommended for marketing authorisation
in the European Union (EU) for expanded use to include children and adolescents 
with paroxysmal nocturnal haemoglobinuria (PNH).

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines
Agency based its positive opinion on interim results from the Phase III clinical
trial in children and adolescents with PNH, which were recently presented during
the European Hematology Association 2021 Virtual Congress.

This trial demonstrated that _Ultomiris _was effective in achieving complete C5 
complement inhibition through 26 weeks for the treatment of children and adolescents
up to 18 years of age with PNH. Additionally, _Ultomiris _had no reported treatment-
related severe adverse events, and no patients discontinued treatment during the
primary evaluation period or experienced breakthrough haemolysis, which can lead
to disabling or potentially fatal blood clots.^(1)

The efficacy and safety of _Ultomiris _in children and adolescents is consistent
with the established profile of _Ultomiris _in clinical trials involving adults 
with PNH and is representative of the broad PNH patient population seen in the real-
world clinical setting.^(2,3)

PNH is an ultra-rare and severe blood disorder characterised by the destruction 
of red blood cells that can cause a wide range of debilitating symptoms and complications,
including thrombosis (blood clots), which can occur throughout the body, and result
in organ damage and potentially premature death.^(1,4-6)

> **Austin Kulasekararaj, MD, King’s College Hospital, London, United Kingdom, said**:“
> PNH can have a significant and devastating impact on a child’s quality of life,
> and it can be overwhelming for families to manage their disease. The potential
> approval of _Ultomiris_, which offers the efficacy and safety already established
> with _Soliris_ (eculizumab) and requires fewer treatments each year, would have
> a meaningful impact for children with PNH and their families.”

> **Marc Dunoyer, incoming Chief Executive Officer, Alexion, said**: “This recommendation
> shows that _Ultomiris_ – which has become the standard of care for the treatment
> of adults with PNH – has the potential to transform the lives of children and 
> adolescents in Europe suffering from this devastating rare disease. As we listen
> to the patient community and understand the challenges of living with a rare disease,
> we recognize the importance of continuing to deliver options and formulations 
> that enhance patient care and disease management.”

The CHMP recommended the expanded use of _Ultomiris _to include children (with a
body weight of 10 kg or above) and adolescents with PNH who experience haemolysis
with clinical symptom(s) indicative of high disease activity, as well as for individuals
who are clinically stable after having been treated with _Soliris_ for at least 
the past six months.

_Ultomiris _was first approved in the EU in 2019 for the treatment of adults with
PNH and is also approved in the EU for the treatment of adults and children with
atypical haemolytic uraemic syndrome (aHUS). In June 2021, the US Food and Drug 
Administration approved the expanded use of _Ultomiris _to include children (one
month of age and older) and adolescents with PNH, the first and only treatment for
this age group in the US.

**PNH**

Paroxysmal nocturnal haemoglobinuria (PNH) is a serious ultra-rare blood disorder
with devastating consequences. It is characterised by the destruction of red blood
cells, which is also referred to as haemolysis. PNH occurs when the complement system–
a part of the body’s immune system – over-responds, leading the body to attack its
own red blood cells. PNH often goes unrecognised, with delays in diagnosis from 
one to more than five years. Patients with PNH may experience a range of symptoms,
such as fatigue, difficulty swallowing, shortness of breath, abdominal pain, erectile
dysfunction, dark-coloured urine and anaemia. The most devastating consequence of
chronic haemolysis is the formation of blood clots, which can occur in blood vessels
throughout the body, damage vital organs, and potentially lead to premature death.
The prognosis of PNH can be poor in many cases, so a timely and accurate diagnosis–
in addition to appropriate treatment – is critical to improving patient outcomes.

**Ultomiris**

_Ultomiris_ (ravulizumab), the first and only long-acting C5 complement inhibitor,
offers immediate, complete, and sustained complement inhibition. The medication 
works by inhibiting the C5 protein in the terminal complement cascade, a part of
the body’s immune system. When activated in an uncontrolled manner, the complement
cascade over-responds, leading the body to attack its own healthy cells. _Ultomiris
_is administered intravenously every eight weeks or, for paediatric patients less
than 20 kg, every four weeks, following a loading dose. _Ultomiris _is approved 
in the US for the treatment of adults and children (one month of age and older) 
with PNH, as well as in the EU and Japan as a treatment for adults with PNH. It 
is also approved in the US for aHUS to inhibit complement-mediated thrombotic microangiopathy
in adult and paediatric (one month of age and older) patients, in the EU for the
treatment of adults and children with a body weight of at least 10 kg with aHUS,
as well as in Japan for adults and children with aHUS.

**Alexion**

Alexion, AstraZeneca Rare Disease, is the group within AstraZeneca focused on rare
diseases, created following the 2021 acquisition of Alexion Pharmaceuticals, Inc.
As a leader in rare diseases for nearly 30 years, Alexion is focused on serving 
patients and families affected by rare diseases and devastating conditions through
the discovery, development and commercialisation of life-changing medicines. Alexion
focuses its research efforts on novel molecules and targets in the complement cascade
and its development efforts on haematology, nephrology, neurology, metabolic disorders,
cardiology, ophthalmology, and acute care. Headquartered in Boston, Massachusetts,
Alexion has offices around the globe and serves patients in more than 50 countries.

Share on:
